Compare Natera Inc. Common Stock (NTRA) vs Weyerhaeuser Company Common Stock (WY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Weyerhaeuser Company Common Stock — how do they compare? Natera Inc. Common Stock trades at $393.93 (market cap $57.03B), while Weyerhaeuser Company Common Stock trades at $19.18 (market cap $13.62B). The key difference: Natera Inc. Common Stock is far larger — about 4.2× Weyerhaeuser Company Common Stock's market cap, and Weyerhaeuser Company Common Stock pays a 4.44% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals.
| NTRA | WY | |
|---|---|---|
Market Cap | $57.03B | $13.62B |
Volume | 1,131,157 | 8,637,043 |
Sector | Health | Real Estate |
52-Week High | $425.64 | $27.10 |
52-Week Low | $179.42 | $18.47 |
Typical Hold Time | 0 Days | — |
Enterprise Value | $56.18B | $18.54B |
Dividend Yield | — | 4.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Weyerhaeuser (WY) trades at $18.97, up 0.16% with neutral technical signals. The stock shows strong earnings momentum, beating estimates for three consecutive quarters, while fundamentals reveal modest profitability with 6.89% net margin and 4.97% ROE. Recent news highlights institutional accumulation and upcoming Q3 earnings on October 29. The company maintains stable revenue at $6.9B but faces cash flow challenges with negative net cash flow of $203M in 2025.
Weyerhaeuser presents a mixed outlook with analyst consensus favoring bullish sentiment (52% buy ratings) and a $29.33 price target suggesting 55% upside. However, risks include weak dividend coverage, high leverage at 5x, and sensitivity to interest rates and housing market cycles. The stock's current proximity to 52-week lows offers potential value but requires careful monitoring of lumber demand recovery and Q3 earnings results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Weyerhaeuser Company Common Stock
Weyerhaeuser Company is a timberland-focused real estate investment trust (REIT) that owns and manages more than 10 million acres of timberland in US, in addition to timberlands under long-term license in Canada. The company also manufactures wood products, including lumber, oriented strand board, and engineered wood.
Read more on WY →
